In a report issued on October 19, Cory Kasimov from J.P. Morgan maintained a Buy rating on Clovis Oncology (NASDAQ: CLVS). The company’s shares closed on Friday at $26.36, close to its 52-week low of $26.13.
According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 1.6% and a 39.4% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Jounce Therapeutics Inc, and Vertex Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Clovis Oncology with a $57 average price target, which is an 116.2% upside from current levels. In a report issued on October 19, SunTrust Robinson also reiterated a Buy rating on the stock with a $90 price target.
.
See today’s analyst top recommended stocks >>
Based on Clovis Oncology’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $101 million. In comparison, last year the company had a GAAP net loss of $60.66 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Clovis Oncology, Inc. engages in the acquisition, development, and commercialization of anti-cancer agents. Its marketed product, Rubraca, seeks to treat patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies. It also has product candidates, namely Rociletinib and Lucitanib.
